Investigating combinations of antibodies to treat and prevent HIV/AIDS
Official title: Broadly neutralizing antibody combinations with single virions in HIV+ plasma
Funded at University of Maryland Baltimore · NIH-10994604 · Data updated 2026-11-12
This study is looking at new ways to use special antibodies to make HIV treatments better, so people living with HIV/AIDS can have more effective options to manage their condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | January 23, 2023 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $374,663 |
| NIH project number | 5R01AI172487-03 |
| Project ID | NIH-10994604 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV/AIDS who are seeking new treatment options or those at high risk for HIV infection.
✕Less likely to help
Patients who are not infected with HIV or those who have already achieved viral suppression with current antiretroviral therapies may not benefit from this research.
What this research studies
This research focuses on developing combinations of broadly neutralizing antibodies (bnAbs) to enhance treatment and prevention strategies for HIV/AIDS. By exploring various combinations of these antibodies, the study aims to improve their effectiveness against different strains of the virus. The approach involves rigorous preclinical testing to identify the most promising antibody combinations that can resist viral escape and provide broader coverage. Patients may benefit from more effective therapies that could lead to better management of HIV/AIDS.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and prevention strategies for HIV/AIDS, potentially improving patient outcomes significantly.
How similar studies have gone: Previous research has shown promise in using combinations of antibodies for HIV treatment, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Ray, Krishanu — University of Maryland Baltimore
- Study coordinator: Ray, Krishanu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.